The World Health Organization (WHO 2003) recognizes 3 endometrial stromal neoplasms: noninvasive endometrial stromal nodule and the 2 invasive neoplasms, endometrial stromal sarcoma (ESS), low grade and undifferentiated endometrial sarcoma (UES). It is important to note that the WHO 2003 does not define moderate atypia (an important differentiating diagnostic criterion for ESS, low grade and UES), nor does it discuss its significance. Moreover, studies on reproducibility and additional prognostic value of other diagnostic features in large are lacking. Using strict definitions, we analyzed the agreement between routine and expert-review necrosis and nuclear atypia in 91 invasive endometrial stromal neoplasias (IESN). The overall 5-year and 10-year recurrence-free survival rate estimates of the 91 IESN patients were 82% and 75%, respectively. Necrosis was well reproducible, and nuclear atypia was reasonably well reproducible. The 10-year recurrence-free survival rates for necrosis absent/inconspicuous versus prominent were 89% and 45% (Po0.001) and those for review-confirmed none/mild, moderate, severe atypia were 90%, 30%, and o20% (Po0.00001). Therefore, cases with moderate/severe atypia should be grouped together. Nuclear atypia and necrosis had independent prognostic values (Cox regression). Once these features were taken into account, no other feature had an independent additional prognostic value, including mitotic count. Using ''none/
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Invasive endometrial stromal neoplasms account for 15% of all uterine sarcomas and for approximately 0.2% to 0.7% of all uterine malignancies (1,2). Originally, endometrial stromal sarcoma (ESS) was low grade or high grade based on mitotic count (3). Subsequently, in 1982, Evans (4) proposed a change in the paradigm used to approach this disease, which was later endorsed by other investigators and ultimately accepted by the World Health Organization classification (WHO 2003) . ESS, low grade refers to densely cellular, invasive endometrial stromal tumors that lack both significant cellular atypia and pleomorphism. The stroma usually displays a rich network of small capillaries and arterioles. Necrosis is typically absent or inconspicuous, but vessel invasion can often be observed (1) . ESS, low grade should be distinguished from endometrial stromal nodule, which lacks infiltrative margins. It should be distinguished also from undifferentiated endometrial sarcoma (UES), which is a high-grade sarcoma that lacks specific differentiation (without histologic resemblance to endometrial stroma), shows significant cellular atypia, and often but not always has prominent necrosis and hemorrhage (1) . The behavior of ESS, low grade is indolent, although late recurrence and distal metastasis may occur. In contrast, UES has a much worse prognosis. Cases exist showing transition of ESS into high-grade sarcomas (5) .
As the definitions of ESS before and after 2003 differ, studies on prognostic factors before 2003 cannot be applied to ESS, low grade diagnosed later. The problem with regard to earlier studies is that the various conditions were aggregated, preventing meaningful analysis of any single variable (6) (7) (8) (9) (10) (11) (12) (13) . Further, some recent studies are still using the older classification (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) 
PATIENTS AND METHODS
The study was approved by the Institutional Review Board of the Fudan University Obstetrics and Gynecology Hospital. The patient cohorts have been described in detail before (28) . In brief, the pathology files at that hospital contained 91 cases of invasive low-grade and high-grade endometrial stromal neoplasms according to the pre-WHO 2003 criteria, the diagnoses of which were independently confirmed by 2 experienced gynecologic pathologists (Xianrong Zhou, Jan P. A. Baak). Stage was determined using the 2009 FIGO rules for staging of endometrial and leiomyosarcomas (29, 30) . Diagnostic criteria per WHO 2003 assessed the absence or presence of prominent necrosis and the degree of nuclear atypia, which we assessed using the features proposed by Kempson and Hendrickson (31) . Tumor cell necrosis, as opposed to other forms of necrosis, shows a relatively abrupt transition between necrotic and preserved cells. The nuclear ghost outlines of the 300 W. FENG ET AL.
necrotic cells can often be seen throughout the necrotic area, and inflammatory cells are uncommon. Necrosis is usually conspicuous in UES, the size exceeding more than half of a field of vision with a 40 times objective (about 0.4 to 0.6 mm in diameter). Assigning the degree of atypia took into account the degree of nuclear pleomorphism, nuclear size, nuclear membrane irregularities, chromatin density, and nucleolar size and prominence. Mildly (insignificantly) atypical cells show minimal variation in nuclear size and shape, and nucleoli are small. Moderate atypia shows scattered pleomorphic nuclei. Severe atypia shows many and severely pleomorphic nuclei. As only few cases showed no nuclear atypia, we grouped the atypia as none/mild. For analysis, we thus distinguished none/mild and separately distinguished moderate and severe atypia. Although moderate and severe atypia were evaluated separately, whenever appropriate they have been reported together as moderate/severe. 
Statistic Analysis
SPSS version 15 (SPSS; Chicago, IL) was used for the statistical analyses. To study the reproducibility of necrosis and cellular atypia, cross tables were constructed for these features, as mentioned in the pathology reports routinely made and as assessed by the reviewing gynecologic pathologists. Cross tables were also constructed for stage on the one hand and for necrosis and cytologic atypia on the other. The percentage and significance of overall agreement were calculated. The prognostic significance of the variables was assessed using the Kaplan-Meier survival analysis, with recurrence-free survival and overall disease-related survival as end points. The hazard ratios (HRs) and 95% confidence intervals of the various features were calculated by univariate regression analyses (Cox, Forward, and Wald). Multivariate regression (the Cox model) was used to assess the independent additional prognostic value of the different features studied.
RESULTS
The patients were 19 to 66 years of age (median, 43 yr). With a median follow-up of 5.8 years (range, 0.5 to 39 yr), there were 18 recurrences and 13 tumorrelated deaths. The Kaplan-Meier estimates of the 5-year and 10-year recurrence-free survival rates were 82% and 75%, respectively. For the 91 cases, the original researchers and reviewers agreed completely about necrosis (absent or inconspicuous vs. prominently present), which is an important criterion for the diagnosis of ESS, low grade versus UES. Nuclear atypia was only partially reproducible (86% agreement), especially moderate atypia (29% agreement between the original routine and the review diagnoses). However, the reviewing pathologists (using the strict criteria for moderate atypia mentioned above) agreed on moderate atypia in all cases (after discussion and careful comparison with other normal endometrial stroma and with mildly, moderately, or severely atypical cases, using a double-headed microscope).
Prognosis, as might be expected, is related to stage. Most of the tumors were at Stage 1 (86%), and the prognosis was good (88% at 5 yr and 82% at 10 yr), Tables 2 and 3 show correlations between stage of necrosis and atypia. Necrosis increased from 9% in Stage 1 to 17% in Stage 3 (P = 0.004). Moderate and severe atypia also occurred significantly more often in Stages 2 and 3 (P = 0.04). Nuclear atypia and necrosis were significantly correlated (P = 0.002), with moderate and severely atypical tumors showing necrosis more often (Table 4) , even though no prediction could be made in an individual case. Analysis of the mitotic count showed that 66 of the 68 WHO 2003-defined ESS, low grade had values o10/10 high-power fields. In contrast, the majority of UES (56%) had values Z10/10 highpower fields.
Multivariate survival analysis (Cox model) of all features showed that atypia and necrosis had independent prognostic values ( Table 5 ). The combination of atypia and necrosis is significantly stronger than any individual feature alone. The 5-year and 10-year recurrence-free survival rates for necrosis absent/inconspicuous were 89% and 80%, respectively, and those for prominent necrosis were 45% and 45%, respectively Po0.001, (Fig. 2) . For mild atypia, the 5-year and 10-year recurrence-free survival rates were 92% and 86%, and for moderate atypia 29% and 29%, respectively. For cases with severe atypia, the last patient was followed up for 5.3 years, and therefore 10-year follow-up was not reached. The 5-year recurrence-free survival rate was 17% Po0.00001, (Fig. 3) . Therefore, the most impressive prognostic difference is between cases with none/mild versus moderate/severe atypia. In fact, the current survival data indicated that cases with moderate and severe atypia were prognostically not different from each other and should be grouped together against cases with none or mild atypia (Table 6 ), a conclusion drawn from univariate and multivariate proportional HR analyses (the Cox model).
Combinations of nuclear atypia and prominence of necrosis were evaluated for the most significantly prognostic groupings (Table 7 ). The first classification rule was ''no+mild+moderate atypia combined with absent or inconspicuous necrosis'' as ESS, low grade, versus all other cases with ''either prominent necrosis present, or prominent necrosis absent but with severe atypia'' as UES. This rule resulted in 73 ESS, low grade and 18 UES cases, with 10-year recurrence-free survival rates of 89% and 44%, respectively (Po0.0001, HR = 7.1) and overall mortality-free survival of the ESS, low grade and UES according to this rule of 95% and 50%, respectively (Po0.0001, HR = 11.6). The second rule differed 
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slightly: the atypia present was only none/mild as ESS, low grade, versus all other cases as UES. This resulted in 68 ESS, low grade and 23 UES cases with 93% versus 44% recurrence-free survival (Po0.0001, HR = 10.8, Fig. 4A ) and 99% versus 48% diseasespecific overall mortality-free survival (Po0.00001, HR = 45.4, Fig. 4B ). Thus, 5 ESS, low grade cases according to the first rule were classified as UES by the revised second classification rule. In support of the second rule definition, 3 of these 5 cases recurred, and 1 patient died from recurrent disease. Comparison of the prognostic outcomes of the 2 rules by multivariate analysis confirms that the second classification rule indeed is the strongest.
Comparison of the original low/high-grade ESS and the WHO 2003 diagnoses (Table 8) In the WHO 2003 description, the definition of ESS, low grade is somewhat ambiguous (''tumors without significant cellular atypia and pleomorphism''). Usually, most pathologists grade nuclear atypia as none, mild, moderate, and severe, or as low and high. In the WHO 2003 description, even though moderate atypia is not discussed, we felt it important to determine whether this middle category had important prognostic value and also determine the reproducibility of these various nuclear atypia grades and necrosis. Mild (insignificant) atypia showed minimal variation in nuclear size and shape, and nucleoli were small. Quite commonly, mild and no atypia were difficult to distinguish and hence were combined into a single category. Moderate atypia was defined as cases showing scattered pleomorphic nuclei, and severe atypia was classified as having many and severely pleomorphic nuclei. The absence or presence of prominent necrosis is also easily reproducible. Cases with severe atypia are easy to diagnose, and in our study half of these cases also had necrosis. Thus, both atypia and necrosis proved to be strong independent prognostic indices; however, with the incorporation of moderate atypia with severe atypia, the prognostic value increased and, when tied with prominent necrosis, became the strongest yet. Of concern is still the potential interobserver variation in the category of moderate atypia that might occur if viewed without strict rules of classification. It may be that, in the future, immunohistochemical markers e.g., proliferation biomarkers (33) or morphometric features may be of help. Until recently, morphometric assessments were tedious, but the advent and rapid spread of digital pathology will probably change this markedly.
Several issues have not been addressed and are beyond the scope of this manuscript to resolve. One is the validity of considering UES as an entity distinct from ESS, low grade as opposed to being one end of the spectrum with ESS, low grade being at the other. By analogy, should Grade 3 endometrial adenocarcinoma be potentially considered as a different entity from Grade 1 endometrial carcinoma, as both have differing prognoses even though both seem to arise by the same mechanism? In contrast, evidence now points to why borderline serous tumor/Grade 1 serous carcinoma of the ovary is a completely different entity from high-grade serous carcinoma, as both seem to arise by different pathogenetic mechanisms even though they share many histomorphologic features. For example, the former is KRAS and BRAF positive, and the latter is KRAS and BRAF negative. Issue 2 is whether the WHO 2003, in eliminating the category of high-grade ESS, has simply substituted UES in its place (Old dog, New name). Finally, Issue 3 is should the category of ESS high grade be reintroduced if it is shown to differ in some fundamental way from a subset of the current UES cases? Future studies based on immunohistochemical, molecular pathology and even wholegenome sequencing may resolve these conundrums.
In conclusion, the WHO 2003 criteria for classifying endometrial stromal tumors as ESS, low grade versus UES are somewhat ambiguous; however, on the basis of our definitions for atypia grades and necrosis, our findings result in 2 prognostically strong and separate categories. The major distinguishing features are atypia that is moderate or severe on the one hand and none or mild on the other. Further, the presence of necrosis is also an important distinguishing feature. 

